Font Size: A A A

COVID-19 Vaccine Planning

COVID-19 Vaccine Planning

This is a centralized resource where you'll find everything you need to know to be ready to administer COVID-19 vaccine. We’ll regularly update this page as more information is available. 

Social Media Resources


Download a Profile Image for Social Media

Download a Sign for Photos/Posting in your Workplace
Editable Word Doc - add an organization logo
Editable Word Doc - Spanish
PDF - Spanish

Nevada Resources

Videos, Flyers, Multiple Language Resources

From Concern to Confidence - How Physicians Can Build Trust in COVID-19 Vaccines

Technical Bulletins
Access all bulletins

8.25.21 Regulatory Updates for COVID-19 Vaccines - FDA Approval of Pfizer-BioNTech COVID-19 Vaccine

8.18.21 Recommendations for COVID-19 Vaccination for People Who are Pregnant or Breastfeeding

8.18.21 Additional mRNA COVID-19 Dose Recommended for Moderately and Severely Immunocompromised Individuals

7.2.21 ACIP Discussions on Myocarditis Post-COVID 19 Vaccination and Potential Need for COVID-19 Booster Doses

5.27.21 COVID-19 Vaccines May Now Be Coadministered

5.18.21 Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to adolescents ages 12-15 years

5.4.21 Resuming use of Janssen Vaccine

5.4.21 Adverse Event Reporting Following COVID-19 Vaccination

4.19.21 Storage and Handling of COVID-19 Vaccines

3.3.21 Nevada Implementation of Janssen Vaccine

Janssen COVID-19 Vaccine

Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers

Janssen COVID-19 Fact Sheet for Patients

Fact Sheet on Vaccines and Fetal Cell Lines (Immunize Nevada)

Fact Sheet on Janssen Vaccine (Immunize Nevada)

ACIP Recommendation for Use of Janssen COVID-19 Vaccine

Janssen Vaccine Storage and Handling Summary

Janssen Vaccine Storage and Handling Labels

Transport Guidance Summary

Transport Temperature Log

Janssen Standing Orders

Janssen Training Module

Janssen Preparation and Administration Summaryz

Pfizer-BioNTech and Moderna Resources

What Clinic Personnel Need to Know

Interim Considerations: Preparing for the Potential Management of Anaphylaxis After COVID-19 Vaccination

Screening Form

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines

Moderna COVID-19 Vaccine

Moderna Vaccine Storage and Handling Summary

Moderna Training Module

Moderna Preparation and Administration Summary

Moderna Vaccine Lot 41L20A Technical Bulletin

Moderna COVID-19 Vaccine Information

Moderna COVID-19 Vaccine Standing Orders

Moderna COVID-19 Vaccine Fact Sheet for Healthcare Providers

Moderna COVID-19 Vaccine Fact Sheet for Patients
Moderna COVID-19 Vaccine Fact Sheet for Patients - Translation in 6 languages

Pfizer-BioNTech Vaccine

Pfizer-BioNTech Storage and Handling Summary

Pfizer-BioNTech Training Module

Pfizer-BioNTech Preparation and Administration Summary

Pfizer- BioNTech Storage and Handling Checklist

Pfizer-BioNTech Vaccine Information

Pfizer-BioNTech Vaccine Standing Orders

Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers

Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Patients
Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Patients - Translation in 20 languages

CDC Resources

COVID-19 Prevaccination Checklist

Long-Term Care Facility Toolkit: Preparing for COVID-19 Vaccination at Your Facility

CDC COVID-19 Vaccination Program Provider Requirements and Support

COVID-19 Vaccination Communication Toolkit for Medical Centers, Clinics, and Clinicians

10 Things Healthcare Professionals Need to Know

Hosting Mass Immunization Clinics

COVID-19 ACIP Vaccine Recommendations

VaccineFinder Reporting and Finder System

Answering Patients' Questions

Vaccine Administration and Other Resources

Standing Orders and Screening Checklist

Satellite, Temporary, and Off-Site Vaccination Clinic Supply Checklist

Vaccine Storage and Handling with COVID-19 Vaccine Addendum

COVID-19 Vaccine Training Modules

Clinical Training and Resources for Healthcare Professionals

Fever and Vaccines

COVID-19 Vaccine Training through TRAIN

Vaccine Administration Job Aids

Billing and Coding Resources

Payor information for COVID-19 vaccine for immunocompromised individuals

COVID-19 Vaccine Toolkit for Health Insurance Issuers and Medicare Advantage Plan Payers (PDF)

COVID-19 Vaccine Policies and Guidance - CMS

CPT Code set for Coronavirus Immunizations

HRSA COVID-19 Claims Reimbursement - Uninsured Patient Program

Specific Insurance Plan Guidance

Frequently Asked Questions

COVID-19 Vaccine Development

What is the FDA’s role in approving vaccines and what is being done to produce a COVID-19 vaccine?

The FDA regulates vaccines. Vaccines undergo a rigorous review of laboratory and clinical data to ensure the safety and effectiveness of these products. Approved vaccines may also be required to undergo additional studies to further evaluate the vaccine and often to address specific questions about the vaccine's safety, effectiveness, or possible side effects. The FDA is expediting clinical trials for vaccines by providing timely advice to and interactions with vaccine developers. The FDA is also supporting product development and scaling up of manufacturing capacity for high priority vaccines for COVID-19.

Is the COVID-19 vaccine being studied in children or pregnant women?

As with most vaccines, studies will need to be conducted in children and in pregnant women, but these studies are often done after the vaccine has been shown to work and be safe in healthy adults. Given the current circumstances, the Food and Drug Administration (FDA) has encouraged vaccine manufacturers to consider including pregnant women in the current studies. Children will most likely be studied after one or more vaccines are approved. 

COVID-19 Vaccine Distribution

Who will get the COVID-19 vaccine first?

At first, there may be a limited supply of COVID-19 vaccine(s). Operation Warp Speed will work to get those first vaccine doses out once a vaccine is authorized or approved and recommended, rather than waiting until there are enough vaccines for everyone. However, it is important that the initial vaccines are given to people in a fair, ethical, and transparent way. The goal is for everyone to be able to easily get a COVID-19 vaccine as soon as large quantities are available. Whether it’s at their doctor’s office, retail pharmacy, hospital, or federally qualified health center, several thousand vaccination providers will be available so no one will have to travel far to be vaccinated.

When will a COVID-19 vaccine be available?

Vaccines will be available when they are demonstrated to be safe and effective in large phase 3 clinical trials, have been approved by the FDA, and have been manufactured and distributed to places where people can be vaccinated. The United States government and others have heavily invested in building the manufacturing capacity to produce large numbers of vaccine doses before the findings of the phase 3 trials are available. This accelerated development does not imply short-cuts or that safety, scientific or ethical integrity are compromised.

How does a facility receive COVID-19 Vaccine distribution?

If you are interested in stocking and administering the COVID-19 vaccine and meet the requirements below, please fill out this survey

  • You are enrolled in NV WEBIZ.
  • You have a stand-alone freezer and a stand-alone refrigerator with digital temperature monitoring devices for vaccine storage.

How does a facility request a data logger?

If a facility needs a data logger, they should include their request in the REDCap enrollment survey.

If a site has an Ultra-Cold Freezer, can they request for a direct shipment of vaccine?

Yes, but only if the site also has the means to administer the 975 minimum doses required for a direct shipment.

Will facilities be able to coordinate how much allocation they want to pull at a time? Will facilities be able to stagger their dose allocation so they do not have to vaccinate entire staff units at once?

Yes. Facilities will be able to request how much of their allocation they want for each shipment. Hospitals and facilities will be able to receive multiple shipments of vaccines to avoid creating even more strain on an already low health care provider workforce.

When can facilities expect vaccine distribution?

Although COVID-19 vaccine manufacturing and distribution is an ever-changing event, we are currently planning for an early December vaccine distribution for hospitals.

COVID-19 Vaccine Information

How many doses of COVID-19 vaccine will be needed?

All but one of the COVID-19 vaccines currently in phase 3 clinical trials in the United States use two doses. The other COVID-19 vaccine uses one dose. When giving two doses, they are usually given one or two months apart. We will need to wait for the results of the clinical trials to have more information about how many doses will be needed. 

How do we know the COVID-19 vaccine will be safe?

Independent advisory committees to the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) review vaccine safety and effectiveness data before any vaccine is approved or allowed for distribution under Emergency Use Authorization. Vaccines will not be released for use until deemed safe and effective by these committees. In order to speed up the distribution process, Operation Warp Speed is manufacturing vaccines while they are in clinical trials with the intention of throwing them away if the vaccine is not deemed safe and effective at the conclusion of the clinical trial. 

Will COVID-19 vaccines contain a microchip?

COVID-19 vaccines will not contain microchips. This idea is based on a false narrative and misinformation campaign being waged online. 

Will COVID-19 vaccines alter people’s DNA?

No. There is no evidence the vaccines would alter any part of your genomic DNA. These vaccines are “mRNA” vaccines, which use a fragment of genetic material from the virus rather than a weakened or killed version of the virus, to produce an immune response

Will the COVID-19 vaccine be free?

Under the CARES Act, health insurance, insurers and plans are required to cover any ACIP recommended COVID-19 preventive service, including vaccines, without cost sharing from both in and out-of-network providers during the course of the public health emergency (PHE). As a condition of receiving free COVID-19 vaccines from the federal government, providers will be prohibited from charging consumers for administration of the vaccine. For individuals who are uninsured, providers will be able to be reimbursed for administering the COVID-19 vaccine to individuals without insurance through the Provider Relief Fund, administered by the Health Resources and Services Administration (HRSA).

Since this vaccine is producing an immune response, would someone who received the vaccine then also test positive for COVID-19?

No. A COVID-19 vaccine administration will NEVER yield a positive COVID PCR test result, regardless if a patient has a low-grade fever or not. The vaccine makes the muscle cells produce the spike protein and antibodies are formed to the spike protein. For a test to be positive, there must be viral RNA in the nose. The vaccine does not cause that.

How long is received vaccine viable for? Can vaccine vials be refrigerated after they have been thawed out?

Once vaccine vials have been pulled out of their Ultra-Cold Storage Units, they are viable for up to 5 days in refrigerators. The ultra-cold vaccine, Pfizer product, vials cannot be refrozen. They must only be thawed out with the intention of using them within 5 days of removal from the ultra-cold freezer. Once a vial has been diluted it must be used within 6 hours

COVID-19 Vaccine Reporting

How often must vaccination data be reported?

Vaccination data should ideally be reported within 24 hours, but no later than 72 hours.